News & Updates

Rapid antigen test: Don’t let perfect be the enemy of good

23 Oct 2021 by

While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.

Rapid antigen test: Don’t let perfect be the enemy of good

23 Oct 2021

Rapid COVID-19 testing: Is it as good in kids?

20 Oct 2021 by

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Rapid COVID-19 testing: Is it as good in kids?

20 Oct 2021

Optimising diabetes management and improving utilisation of healthcare resources with insulin glargine biosimilars

13 Oct 2021

Diabetes burden and associated complications are on the rise in Singapore and contribute to the increasing healthcare expenditure. Insulin biosimilars, with comparable efficacy and safety to the originator biologics, can help reduce both financial and disease burden. INSTRIDE-1/2 studies have proven biosimilar insulin glargine to be non-inferior to reference insulin glargine with no clinically meaningful differences in terms of efficacy and safety in type 1 and type 2 diabetes patients. Whilst INSTRIDE-3 has proven the switch from reference glargine to a cost-effective biosimilar insulin glargine to be a safe and feasible approach. There is a continued need to educate clinicians to help motivate patients and improve their awareness on biosimilars.

Optimising diabetes management and improving utilisation of healthcare resources with insulin glargine biosimilars

13 Oct 2021

The role of apixaban in managing venous thromboembolism

01 Oct 2021

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), carries a significant morbidity risk. Risk factors for VTE include surgery, hospitalization, pregnancy, contraceptive use, older age, overweight, and obesity. Dr Lee Yuh Shan, a haematologist at Gleneagles Hospital and Mount Elizabeth Novena Hospital, Singapore, explains how newer drugs such as apixaban (Eliquis, Pfizer) address the challenges posed by conventional VTE management therapies.

The role of apixaban in managing venous thromboembolism

01 Oct 2021

Treating iron deficiency in patients with heart failure: The role of ferric carboxymaltose

29 Sep 2021

Iron deﬁciency (ID) is common among patients with heart failure (HF), aﬀecting up to 55 percent of patients with stable chronic heart failure (HF) and up to 83 percent of patients with acute decompensated heart failure. [J Am Coll Cardiol 2018;71:782-793]

Treating iron deficiency in patients with heart failure: The role of ferric carboxymaltose

29 Sep 2021

Clinical benefits of flash glucose monitoring with FreeStyle Libre™

15 Sep 2021

Various studies have shown the beneficial effects of the FreeStyle Libre™ flash glucose monitoring system for the continuous monitoring of glucose levels in type 1 and type 2 diabetes (T1D and T2D) patients. While clinical trials have demonstrated a reduced time in hypoglycaemia, fewer hypoglycaemic events per day, and significant reduction in glycated haemoglobin (HbA1c), real-world data have shown improved glycaemic control in these patients.

Clinical benefits of flash glucose monitoring with FreeStyle Libre™

15 Sep 2021

Optimising glycaemic control with FreeStyle Libre™ for better patient management

15 Sep 2021

The FreeStyle Libre™ flash glucose monitoring system includes a sensor which automatically measures and continuously stores up to 8 hours of glucose readings, allowing patients to monitor their glucose levels without the need for painful finger pricks. Physicians play an important role in reviewing and analysing glucose data that is available through LibreView to support patient management.

Optimising glycaemic control with FreeStyle Libre™ for better patient management

15 Sep 2021

2021 EHRA practical guide on NOACs in AF: What’s new, what’s hot

30 Aug 2021 by

Non-vitamin K antagonist oral anticoagulants (NOACs) are the preferred choice of anticoagulants for stroke prevention in patients with atrial fibrillation (AF) in international guidelines. A leading expert in the field, Senior Consultant Cardiologist Dr Teo Wee Siong from Mount Elizabeth Medical Centre, Singapore, shared his insights on the 2021 EHRA* practical guide on NOACS in AF, how to personalize NOACs therapy, including apixaban (Eliquis, Pfizer), and manage difficult treatment scenarios. Dr Teo was past President of APHRS** and is currently President of HRAS***.

2021 EHRA practical guide on NOACs in AF: What’s new, what’s hot

30 Aug 2021

Managing hyponatraemia in patients with heart failure

30 Aug 2021

Hyponatraemia has been associated with poor outcomes in patients with heart failure (HF).¹ Tolvaptan is an oral, selective V2 receptor antagonist, indicated for the treatment of clinically significant hypervolaemic or euvolaemic hyponatraemia (associated with HF or syndrome of inappropriate antidiuretic hormone secretion [SIADH]) with either a serum Na⁺ concentration <125 mmol/L or less marked hyponatraemia that is symptomatic and resistant to fluid restriction.² Trials have demonstrated the efficacy of tolvaptan for augmenting diuresis when administered with furosemide for management of congestive HF.^2,3 The following case studies illustrate the use of tolvaptan in this setting.

Managing hyponatraemia in patients with heart failure

30 Aug 2021

Current management of nosocomial and community-acquired pneumonia in ICU patients with novel antibiotics

27 Aug 2021 by

Nosocomial pneumonia serves as a paradigm for all severe infections, and appropriate antibiotic therapy is the key determinant of patient outcomes. Most data for the use of antibiotics are derived from studies in non-ICU patients and ignore critical care issues such as fluid resuscitation, mechanical ventilation, and changing renal function. Against the backdrop of increasing antimicrobial resistance and the COVID-19 pandemic, how do we optimize antibiotic administration in the ICU? Professor Andrew Shorr from Washington Hospital Center, Georgetown University, Washington DC, US discussed this burning issue at a Pfizer-sponsored satellite symposium, held during the Asia Pacific Intensive Care Symposium (APICS) 2021.

Current management of nosocomial and community-acquired pneumonia in ICU patients with novel antibiotics

27 Aug 2021

News & Updates

Filter by Specialty:

Specialty:

Rapid antigen test: Don’t let perfect be the enemy of good

Rapid antigen test: Don’t let perfect be the enemy of good

Rapid COVID-19 testing: Is it as good in kids?

Rapid COVID-19 testing: Is it as good in kids?

Optimising diabetes management and improving utilisation of healthcare resources with insulin glargine biosimilars

Optimising diabetes management and improving utilisation of healthcare resources with insulin glargine biosimilars

The role of apixaban in managing venous thromboembolism

The role of apixaban in managing venous thromboembolism

Treating iron deficiency in patients with heart failure: The role of ferric carboxymaltose

Treating iron deficiency in patients with heart failure: The role of ferric carboxymaltose

Clinical benefits of flash glucose monitoring with FreeStyle Libre™

Clinical benefits of flash glucose monitoring with FreeStyle Libre™

Optimising glycaemic control with FreeStyle Libre™ for better patient management

Optimising glycaemic control with FreeStyle Libre™ for better patient management

2021 EHRA practical guide on NOACs in AF: What’s new, what’s hot

2021 EHRA practical guide on NOACs in AF: What’s new, what’s hot

Managing hyponatraemia in patients with heart failure

Managing hyponatraemia in patients with heart failure

Current management of nosocomial and community-acquired pneumonia in ICU patients with novel antibiotics

Current management of nosocomial and community-acquired pneumonia in ICU patients with novel antibiotics